South Korea-based NAVER D2SF, NAVER's inhouse corporate venture arm, has invested in ImpriMed, a Silicon Valley-based precision medicine company, joining ImpriMed's $10 million Series A2 bridge round.
ImpriMed develops AI-driven precision medicine solutions that combine ex vivo analysis of patient-derived live cancer cells with genomic, immunophenotypic, and clinical data to support personalised treatment decisions.
At the core of ImpriMed's xCellSense® platform is its ability to keep patient cancer cells viable ex vivo for extended periods, enabling evaluation of their biological characteristics and drug sensitivity. The platform combines these results with immunophenotypic, genomic, and clinical data to guide treatment decisions. ImpriMed is developing AI models trained on more than 3.5 million data points, combining real-world data with functional cell analysis to improve predictive accuracy.
ImpriMed is preparing to commercialise products for blood cancers and blood infection, targeting FDA clearance and CLIA certification by Q1 2027 for an initial US launch.
The company has also established business partnerships with major US hospitals as it builds its human health presence in North America. In South Korea, ImpriMed has developed software for multiple myeloma prognosis and therapy-response predictions. The software has been designated an Innovative Medical Device by the Ministry of Food and Drug Safety (MFDS) and is progressing through the approval and commercialisation process.
ImpriMed also collaborates with leading tertiary hospitals, including Catholic University Seoul St. Mary's Hospital, Seoul Asan Medical Center, and Gangneung Asan Hospital.
The $10 million bridge round follows ImpriMed's $23 million Series A in 2023. The round was led by LB Investment, with participation from new investors NAVER D2SF, Samsung Securities, and Alois Ventures, as well as follow-on investments from existing investors BonAngels and Han River Partners.
